Is Liminatus Pharma financially healthy?
Not really
Liminatus Pharma earns only -32.0 times its interest bill, which leaves little room.
The numbers behind it
Net debt / EBITDA0.0 years
Cash vs. debt$337,655 vs. $1M
Current ratio1.0×Short-term assets for each $1 of bills due within a year
Interest coverage-32.0×How many times operating profit covers the interest bill
How we decide
We measure debt in years of earnings (net debt / EBITDA): under 1 is very comfortable, 1 to 3 is manageable, above 3 is heavy. A company that earns less than 3 times its interest bill also counts as weak.
More questions about Liminatus Pharma
Data as of Nov 13, 2026.